Among these, the targeted immune-fluorescence imaging is the most promising TFI modality in the field of head and neck cancer surgical navigation due to tissues over-expressing EGFR which can be targeted by FDA-approved EGFR antibodies (e.g., cetuximab, panitumumab). The gene discussed is EGFR; the disease is head and neck cancer.